Samsung Active Asset Management Launches New Active ETF in U.S. Biotech Sector
Samsung Active Asset Management has pioneered the launch of Korea's first active ETF focusing on mid-sized U.S. biotech and healthcare firms, named 'KoAct U.S. BioHealthcare Active ETF'. The fund stands out for its ability to promptly incorporate promising biotech companies through AI technology, keeping pace with the fast-growing global AI healthcare market. With a keen eye on generating significant returns, the ETF targets investment opportunities in leading firms within the innovative drug and medical device sectors.
This new ETF by Samsung aims to serve as a U.S. version of domestic biotech ETFs, particularly targeting mid-sized firms with high potential for M&A. Meanwhile, Mirae Asset Management and Shinhan Asset Management have also recorded impressive performances with their ETFs that focus on AI, biotech, and tech industries. These developments are offering global investors fresh avenues for high returns, spotlighting the synergistic potential of AI and biotech healthcare innovations.
Related ETF
Related News
[ETF Grab] Samsung Active, Mirae Asset, Shinhan Asset Management - Prime Economy[Prime Economy] The Exchange-Traded Fund (ETF) market is experiencing high growth every year. As a result, the competition to dominate the market among asset management companies is intense. 'ETF Grab' is a briefing section that compiles the latest news from the ETF industry that pours in daily. It delivers the latest market trends, investment strategies, and expert analysis all at once. On the 11th, news from Samsung Active Asset Management, Mirae Asset Management, and Shinhan Asset Management ETFs.◆Sam..
Related ETF
Samsung Active Management lists new KoAct US BioHealthcare Active ETF - meconomynews.comSamsung Active Asset Management announced on the 11th that it will list the KoAct US BioHealthcare Active Exchange Traded Fund (ETF). This ETF can be considered the US version of the domestic bio ETF, 'KoAct BioHealthcare Active,' which has a net asset value of 300 billion won. It actively invests in discovering and investing in US biohealthcare companies leading the global innovative therapeutics and medical device industries. Specifically, it focuses on mid-sized biohealthcare companies with promising new drug development pipelines, which are more likely to engage in M&A (mergers and acquisitions), rather than big pharmas focusing on acquisitions, thus seeking excess performance compared to the benchmark.
Related ETF
Samsung Active Management Lists Korea's First 'US Bio Active' ETF - SBS BizSamsung Active Asset Management announced today (11th) that it will list the 'KoAct US BioHealthcare Active' Exchange-Traded Fund (ETF), which invests in selected US biohealthcare companies with technological capabilities. It is the first of its kind in Korea to invest in US biohealthcare companies among active ETFs. This ETF is leading the global innovative therapeutics and medical device industry ...
Korea's First 'US Bio Active ETF'… Samsung Active Asset Management Lists 'KoAct US Bio Healthcare Active' - Seoul Economic DailySecurities > Policy News: Samsung Active Asset Management lists 'KoAct US Bio Healthcare Active', investing in US bio-healthcare companies with technology capabilities...
Related ETF
Samsung Active Management launches Korea's first 'US Bio Active ETF' - Financial NewsSamsung Active Asset Management announced on the 11th that it will newly list the 'KoAct US BioHealthcare Active' ETF, which selects and invests in American bio-healthcare companies with technological capabilities. KoAct US BioHealthcare Active aims to quickly invest in newly emerging bio companies in conjunction with AI...
Related ETF